Tilray Inc TLRY shares are trading higher following news the company purchased a majority position in amended Medmen Enterprises Inc MMNFF convertible notes for about $165.8 million.
Irwin D. Simon, Tilray's Chairman and CEO, said, "Backed by accelerating trends towards legalization globally, we are focused on building the world's leading cannabis-focused consumer branded company with a goal of $4 billion of revenue by the end of our fiscal 2024."
"The investment we are announcing in MedMen securities today, one of the most recognized brands in the $80 billion U.S. cannabis market, is a critical step towards delivering on our objective as we work to enable Tilray to lead the U.S. market when legalization allows," Simon stated.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of the company's sales are in Canada and in the international medical cannabis export market.
TLRY Price Action: The stock is trading higher by 4.2% to $13.67 after hours. Tilray has a 52-week high of $67 and a 52-week low of $4.41.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.